SUMF2: A Potential Drug Target and Biomarker for Formylglycine-Generating Enzyme

Target Name: SUMF2

NCBI ID: G25870

SUMF2

SUMF2: A Potential Drug Target and Biomarker for Formylglycine-Generating Enzyme

Introduction

Formylglycine (FG) is a key intermediate step in the metabolism of protein and has been linked to various diseases, including cancer, neurodegenerative diseases, and aging. The formyl transferase (FT) enzyme, which converts FG to formylglycine, is a crucial enzyme in this pathway. However, altered FT activity or dysfunction have been implicated in the development and progression of numerous diseases, including cancer, neurodegenerative diseases, and aging. The SUMF2 gene, which encodes the FT enzyme, is a promising target for drug development due to its central role in the formation of FG. In this article, we will discuss the SUMF2 gene, its function, and its potential as a drug target and biomarker.

Function of SUMF2

SUMF2 is a gene that encodes the formyl transferase (FT) enzyme, which is responsible for converting FG to formylglycine. FG is a highly reactive center, which can easily accept a variety of functional groups, such as thiol, carbonyl, amino, etc., these The group forms a chemical bond with the active center of the protein, thereby affecting the structure and function of the protein. The FT enzyme catalyzes the conversion of the carbonyl group in FG into the formal aldehyde, thereby causing the FG to generate the formal ylglycine.

The function of SUMF2 is critical in metabolic pathways. The activity of FT enzyme is affected by many factors, including pH value, temperature, substrate concentration, etc. Under the regulation of these factors, FT enzyme can efficiently catalyze the conversion of FG into the form ylglycine, thereby playing a key role in the metabolic pathway.

potential drug targets

As a FT enzyme, SUMF2 itself is a potential drug target. Since FT enzymes play a key role in metabolic pathways, inhibiting the activity or function of FT enzymes may have beneficial effects on a variety of diseases.

First, SUMF2 may have a potential role in the treatment of cancer. The activity of FT enzyme is affected by many factors, including pH value, temperature, substrate concentration, etc. Under the regulation of these factors, FT enzyme can efficiently catalyze the conversion of FG into the form ylglycine. Therefore, by regulating the activity or function of FT enzyme, tumor growth can be inhibited, thereby providing new ideas and methods for cancer treatment.

Secondly, SUMF2 may have a potential role in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc. These diseases are closely related to abnormal activity or function of FT enzyme. By regulating the activity or function of FT enzymes, the symptoms of neurodegenerative diseases can be improved, thus providing new means for treatment.

Furthermore, SUMF2 may be closely related to aging. During the aging process, the structure and function of various biomolecules change, including the activity of FT enzymes. Therefore, aging can be delayed by regulating the activity of FT enzyme, thereby providing new ideas and methods for the research of anti-aging drugs.

Biomarkers

SUMF2 is also a potential biomarker. Because the activity of FT enzyme is affected by many factors, including pH value, temperature, substrate concentration, etc. Therefore, the therapeutic effect of FT enzyme on diseases can be evaluated by detecting its activity or function, thereby providing new methods and ideas for disease diagnosis and treatment.

Conclusion

SUMF2 is a gene closely related to metabolic pathways, and its function is crucial in metabolic pathways. At the same time, SUMF2 is also a potential drug target that can have beneficial effects on a variety of diseases, including cancer, neurodegenerative diseases, and aging. By regulating the activity or function of FT enzymes, tumor growth can be inhibited, symptoms of neurodegenerative diseases can be improved, and aging can be delayed, thus providing new methods and ideas for treatment and diagnosis. Therefore, SUMF2 is a potential drug target and an important target for studying FT enzymes.

Protein Name: Sulfatase Modifying Factor 2

Functions: Lacks formylglycine generating activity and is unable to convert newly synthesized inactive sulfatases to their active form. Inhibits the activation of sulfatases by SUMF1

The "SUMF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets